期刊文献+

血清中HCV抗体与HCV-RNA检测在临床中的应用 被引量:4

Clinical Application of Blood Serum Anti-HCV and HCV-RNA Examination in Diagnosis of Patients With HCV
下载PDF
导出
摘要 目的探讨丙型肝炎病毒抗体与RNA在临床中的应用价值。方法用ELISA法检测934例丙型肝炎可疑患者病毒抗体,用实时荧光定量PCR检测379例丙型肝炎可疑患者病毒RNA。结果934例患者HCV抗体阳性率为19.16%,379例HCV-RNA阳性率为43.01%。53例为两者均做的病人,RNA和Ab均阳性的占52.8%(28/53),均阴性占15.1%(8/53),两者的一致率达67.9%,Ab的阳性率为81.1%(43/53),RNA的阳性率为56.6%(30/53)。结论HCV抗体联合HCV-RNA检测对丙型肝炎的临床诊断有一定的价值。 Objective To investigate the clinical value of serum anti- HCV and HCV - RNA in the diagnosis of hepatitis C patients. Methods Hepatitis C antibody was detected in 934 suspicious patients by ELISA, and HCV- RNA was detected in 379 suspicious patients by real time FQ- PCR. Results The positive rates of HCV antibody and HCV RNA were 19. l 6 % (179/934) and 43.01% (163/379) respectively. Fifty - three patients were tested HCV antibody and HCV - RNA; the positive rate of both of them was 52.8% (28/53), and the negative rate of both of them was 15. 1% (8/53). The consistency rate was 67.9%, the positive rates of HCV antibody and HCV - RNA were 81. 1% (43/53) and 56.6% (30/53) respectively. Conclusions Detection of antibodies against HCV and HCV- RNA plays an important role in clinical diagnosis of hepatitis C.
出处 《实用预防医学》 CAS 2007年第5期1550-1551,共2页 Practical Preventive Medicine
关键词 HCV—RNA HCVAb FQ—PCR ELISA HCV - RNA HCVAb Real time - fluorescent quantitative polymerase chain reaction (rt - FQ - PCR) Enzyme linked immunosorbent assay (ELISA)
  • 相关文献

参考文献4

二级参考文献18

  • 1Vander - Pod CL, Keensink HK, Schasberg W, et al. Infectivity of blood seropositive for hepatitis C virus antiobody. Lancet, 190,335 : 558.
  • 2Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 3Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 4Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 5Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 6Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 7Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 8Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 9Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 10Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.

共引文献755

同被引文献40

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部